NAMSW

NewAmsterdam Pharma recently dosed the first participant in SPINOZA, a Phase 2b, randomized, double-blind, placebo-controlled trial evaluating its CETP inhibitor obicetrapib in about 400 people with preclinical Alzheimer’s disease.

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe.

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C - NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, Sept.

NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value.

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 – – Company to host investor day today at 9:00 AM ET in New York City – NAARDEN, the Netherlands and MIAMI, Aug.

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.